TriVascular
- Company typePrivate
- Founded1998
- HeadquartersSanta Rosa, United States
- Headcount251–500
- GTM typeB2B
- OfferingHardware or Manufacturing
TriVascular firmographics
Firmographics- Name
- TriVascular
- Legal name
- Endologix LLC
- Website
- https://trivascular.com
- Company type
- Private
- Founded year
- 1998
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
TriVascular industry classification
Industry- Product category
- Endovascular Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts (HLAHAFAF)
- akta.pro secondary industries
- Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy) (HLAHAFAE), Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)
Keywords
Where TriVascular is headquartered
LocationHeadquarters
- HQ city
- Santa Rosa
- HQ country
- United States
- HQ region
- North America
Markets served
TriVascular business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Medical Device Sales: Sale of endovascular devices including the EVAR portfolio (ALTO, AFX2), DETOUR System, and Pounce Thrombectomy System. Revenue is generated through capital equipment sales to hospital systems and recurring disposable procedural kit sales for each procedure performed.
- Professional Education & Training Services: Revenue generated through professional education programs including VR procedural training and procedural training courses for physicians learning to use Endologix devices.
Go-to-market motion2 records
Distribution channels4 records
Marketing channels8 records
TriVascular product offering
Product offeringCore offering
TriVascular develops and manufactures endovascular medical devices for the treatment of abdominal aortic aneurysm (AAA) and peripheral artery disease (PAD). The portfolio includes the ALTO and AFX2 EVAR (Endovascular Aneurysm Repair) systems for AAA, the DETOUR System for PAD, and the Pounce Thrombectomy System for vascular intervention. The company also offers physician training services including the first virtual reality (VR) procedural training program for EVAR.
Product overview
Endologix offers a unified portfolio of medical devices for vascular disease treatment, primarily consisting of endovascular products. The core offerings include the ALTO and AFX2 systems for Endovascular Aneurysm Repair (EVAR) of Abdominal Aortic Aneurysms (AAA), the DETOUR System for Peripheral Artery Disease (PAD) treatment, and the Pounce Thrombectomy System for vascular intervention. The company also provides physician training services including innovative Virtual Reality (VR) procedural training programs. The portfolio is complemented by reimbursement resources, clinical evidence, and procedural training support.
Differentiator
Problem solved
Functional benefit
Brands
- DETOUR System: A system for PAD (Peripheral Artery Disease) treatment, including the DETOUR System for endovascular aneurysm repair.
- ALTO
- AFX2
- Pounce Thrombectomy System
Products and services
- ALTO Endovascular Aneurysm Repair (EVAR) device for treating Abdominal Aortic Aneurysm (AAA), with a specific variant designed for women and features addressing anatomical complexities and optimized for procedural outcomes.
- AFX2 Endovascular Aneurysm Repair (EVAR) device for treating Abdominal Aortic Aneurysm (AAA), part of the EVAR portfolio.
- DETOUR System A percutaneous transmural bypass system for treatment of Peripheral Artery Disease (PAD), designed to address complex lesions and chronic total occlusions through an endovascular approach. Includes reimbursement resources, professional education, and patient resources.
- Pounce Thrombectomy System A mechanical thrombectomy system for removing clots from peripheral arteries, acquired and incorporated into the Endologix vascular intervention portfolio.
- Virtual Reality (VR) Procedural Training Immersive virtual reality training programs for physicians, the first to pioneer a new approach to EVAR procedural training with VR technology. Includes DETOUR Professional Education programs.
Companies that use TriVascular
Customer profileSegments3 records
Ideal customer profiles2 records
TriVascular technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
TriVascular partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights6 records
TriVascular competitors and assessment
Company assessmentDirect peers
- Cook Medical: Direct EVAR competitor with the Zenith line of endovascular aortic stent grafts, competing for the same AAA procedural volume and physician relationships in vascular surgery.
- W. L. Gore & Associates: Direct competitor in EVAR with the Gore Excluder and related aortic stent-graft family, serving the same vascular surgeons and hospital vascular surgery departments with established clinical evidence.
- Artivion: Competitor in endovascular aortic intervention via the Jotec stent-graft portfolio (acquired from Jotec), competing directly with ALTO/AFX2 in EVAR and TEVAR procedures.
Regional players
- AngioDynamics: Peripheral vascular and thrombectomy player whose portfolio (including mechanical thrombectomy catheters) intersects with TriVascular/Endologix's PAD and Pounce offerings, especially in U.S. hospital accounts.
Emerging players
- Shockwave Medical: Peripheral vascular intervention company (intravascular lithotripsy) addressing complex PAD lesions; competes for physician mindshare and hospital budget that also funds DETOUR and Pounce procedures.
- Penumbra: Closest direct peer to the newly acquired Pounce Thrombectomy System through the Indigo aspiration platform, competing for the same peripheral arterial and venous thrombectomy procedure volume.
- Inari Medical: Fast-growing thrombectomy specialist (FlowTriever and ClotTriever) that overlaps with the Pounce Thrombectomy System franchise and competes for hospital vascular and interventional radiology accounts.
- Lombard Medical: Smaller specialist in EVAR stent-grafts (Aorfix, Altura), offering a directly comparable AAA-focused product range to TriVascular/Endologix's ALTO and AFX2.
Broad incumbents
- Medtronic: Largest competitor in endovascular aortic repair via the Endurant and Valiant EVAR/TEVAR systems, with a broad portfolio that dwarfs TriVascular/Endologix but competes head-to-head in the same AAA and PAD procedure rooms.
- Abbott: Broad incumbent offering EVAR and peripheral vascular intervention devices (including TREO and earlier endovascular franchises), competing across both the AAA and PAD categories that TriVascular/Endologix serves.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
TriVascular social profiles
Digital presenceTriVascular financial estimates
Financial estimateRevenue estimate
Valuation estimate
TriVascular leadership team
Management profileNumber of profiles
Profiles4 records
TriVascular funding detail
Funding detailFunding overview
Funding rounds9 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TriVascular M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TriVascular
What does TriVascular do?
TriVascular develops and manufactures endovascular medical devices for the treatment of abdominal aortic aneurysm (AAA) and peripheral artery disease (PAD). The portfolio includes the ALTO and AFX2 EVAR (Endovascular Aneurysm Repair) systems for AAA, the DETOUR System for PAD, and the Pounce Thrombectomy System for vascular intervention. The company also offers physician training services including the first virtual reality (VR) procedural training program for EVAR.
Is TriVascular a public or private company?
TriVascular is a private company. It is classified as corporate owned and is currently operating.
When was TriVascular founded?
TriVascular was founded in 1998. It employs 251 to 500 people.
Where is TriVascular based?
TriVascular is headquartered in Santa Rosa, United States, in the North America region.
How does TriVascular make money?
Two revenue lines are on record. Medical Device Sales are the primary driver. The others are professional Education & Training Services.
Who are TriVascular's main competitors?
Direct peers on record are Cook Medical, W. L. Gore & Associates and Artivion. AngioDynamics is listed as a regional player. Emerging players are Shockwave Medical, Penumbra, Inari Medical and Lombard Medical. Broad incumbents are Medtronic and Abbott.
Does TriVascular have an API?
No public API is recorded for TriVascular.
What industry is TriVascular in?
TriVascular's product category is Endovascular Medical Devices. Its primary akta.pro industry code is HLAHAFAF, Endovascular Aortic Repair (EVAR/TEVAR) & Aortic Grafts, with a secondary code of HLAHAFAE, Peripheral Vascular Intervention (PAD Stents, Balloons, Atherectomy). Its NAICS code is 339112 and its SIC code is 3841.